Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib

Schaab, C; Oppermann, F S; Klammer, M; Pfeifer, H; Tebbe, A; Oellerich, T; Krauter, J; Levis, M; Perl, A E; Daub, H; Steffen, B; Godl, K; Serve, H
March 2014
Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p716
Academic Journal
The article presents a study which analyzes the phosphoproteome of human bone marrow. It examines whether researchers can distinguish differentially regulated phospho-sites when equating non-responder and responder samples. The resulting final phospo-signature comprising of five phosphorylation sites separates strongly the classes of non-responder and responder samples.


Related Articles

  • Capillary nano-immunoassay for Akt 1/2/3 and 4EBP1 phosphorylation in acute myeloid leukemia. Sabnis, Himalee S.; Bradley, Heath L.; Bunting, Silvia T.; Cooper, Todd M.; Bunting, Kevin D. // Journal of Translational Medicine;2014, Vol. 12 Issue 1, p1 

    Background Overall cure rates in acute myeloid leukemia (AML) continue to range between 60-65% with disease relapse being a major cause of mortality. The PI3K-Akt-mTOR kinase pathway plays a vital role in pro-survival signals within leukemic cells and inhibition of this pathway is being...

  • BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML. Lin, W-H; Jiaang, W-T; Chen, C-W; Yen, K-J; Hsieh, S-Y; Yen, S-C; Chen, C-P; Chang, K-Y; Chang, C-Y; Chang, T-Y; Huang, Y-L; Yeh, T-K; Chao, Y-S; Chen, C-T; Hsu, J T-A // British Journal of Cancer;1/31/2012, Vol. 106 Issue 3, p475 

    Background:Activating mutations of Fms-like tyrosine kinase 3 (FLT3) constitute a major driver in the pathogenesis of acute myeloid leukaemia (AML). Hence, pharmacological inhibitors of FLT3 are of therapeutic interest for AML.Methods:The effects of inhibition of FLT3 activity by a novel potent...

  • "A STRANGER SAVED MY LIFE".  // Dolly;Feb2014, Issue 518, p82 

    A personal narrative is presented which explores the author's experience of how an anonymous bone marrow donor helped her in surviving acute myeloid leukaemia (AML).

  • Uncertainties in the standard care of acute myelogenous leukemia. Rowe, J M // Leukemia (08876924);Apr2001, Vol. 15 Issue 4, p677 

    Focuses on uncertainties in the standard therapy of acute myelogenous leukemia (AML). Standard for induction therapy in AML; Characteristics of secondary leukemias; Attempts made to determine the role of bone marrow transplantation as consolidation therapy for AML patients in first remission.

  • FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia. Eom, Ki-Seong; Min, Woo-Sung; Kim, Hee-Je; Cho, Byung-Sik; Choi, Su-Mi; Lee, Dong-Gun; Lee, Seok; Min, Chang-Ki; Kim, Yoo-Jin; Cho, Seok-Goo; Lee, Jong-Wook; Kim, Chun-Choo // Medical Oncology;Dec2011, Vol. 28, p462 

    The efficacy of fludarabine in combination with an intermediate dose of cytosine arabinoside, mitoxantrone, and G-CSF (FLANG; fludarabine 30 mg/m/day, cytosine arabinoside 1 g/m/day, mitoxantrone 10 mg/m/day, and G-CSF 300 μg/day for 5 days) was evaluated in patients with refractory or...

  • Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Lee-Sherick, A B; Eisenman, K M; Sather, S; McGranahan, A; Armistead, P M; McGary, C S; Hunsucker, S A; Schlegel, J; Martinson, H; Cannon, C; Keating, A K; Earp, H S; Liang, X; DeRyckere, D; Graham, D K // Oncogene;11/14/2013, Vol. 32 Issue 46, p5359 

    Acute myeloid leukemia (AML) continues to be extremely difficult to treat successfully, and the unacceptably low overall survival rates mandate that we assess new potential therapies to ameliorate poor clinical response to conventional therapy. Abnormal tyrosine kinase activation in AML has been...

  • High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia.  // New England Journal of Medicine;3/25/2010, Vol. 362 Issue 12, p1155 

    A correction to the article "High-Dose Daunorubicin in Older Patients With Acute Myeloid Leukemia" that was published in the September 24, 2009 issue is presented.

  • NPM1 mutations predicted favorable outcome for older patients with AML.  // Hem/Onc Today;1/25/2010, Vol. 11 Issue 2, p43 

    The article focuses on a study which found that older patients with cytogenetically normal acute myeloid leukemia and NPM1 mutations, particularly those aged 70 years or older, had more favorable outcomes than patients with wild-type NPM1.

  • Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells. Weisberg, Ellen; Liu, Qingsong; Zhang, Xin; Nelson, Erik; Sattler, Martin; Liu, Feiyang; Nicolais, Maria; Zhang, Jianming; Mitsiades, Constantine; Smith, Robert W.; Stone, Richard; Galinsky, Ilene; Nonami, Atsushi; Griffin, James D.; Gray, Nathanael // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    Objectives: Tyrosine kinase inhibitor (TKI)-treated acute myeloid leukemia (AML) patients commonly show rapid and significant peripheral blood blast cell reduction, however a marginal decrease in bone marrow blasts. This suggests a protective environment and highlights the demand for a better...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics